December 19, 2014
BTG plc: Appointment of Non-executive Director

London, UK, 19 December 2014

BTG plc (LSE: BTG), the specialist healthcare company, today announces the appointment of Dr. Susan Foden as a non-executive director of the Board, effective from 1 March 2015.

Susan has a background in the field of Biotech and Healthcare and holds a number of Non-Executive positions with both public and private companies. She is currently Chair of BerGenBio AS and Cizzle Biotech Ltd, holds non-executive roles with Vectura Group plc, Evgen Ltd, Source Bioscience plc and is an advisory board member for CD3 (a joint initiative between Leuven University and the European Investment Fund). Previously Susan has held the positions of Investor Director with the venture capital firm Merlin Biosciences, CEO of the technology transfer company, Cancer Research Campaign Technology Ltd and Head of Academic Liaison at Celltech Ltd. She studied Natural Sciences/Biochemistry and has an MA and DPhil from the University of Oxford.

Garry Watts, BTG’s Chairman, commented: “Susan brings a strong track record to BTG, having helped a number of organisations across the sector to develop their businesses. Her significant industry experience will be of great benefit to us as we continue to implement our growth plans.”

There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Services Authority Listing Rules.

For further information please contact:

Andy Burrows, VP, Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605                       

Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536

FTI Consulting
Ben Atwell/Simon Conway
+44 (0)20 3727 1000

About BTG

BTG is an international specialist healthcare company that is developing and commercializing products targeting acute care, cancer and vascular diseases. The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programs and products to develop and market to specialist physicians.

For further information about BTG please visit our website at